Effects of Switching From Deucravacitinib to Tildrakizumab in Psoriasis: A 28-Week Real-World Study. (PubMed, J Psoriasis Psoriatic Arthritis) - Oct 13, 2026 - "Three treatment-related adverse events (AEs) occurred; eczema in 2 patients (13.3%) and arthralgia in 1 patient (6.7%). These preliminary findings suggest that tildrakizumab may be a treatment option for patients with an insufficient response to deucravacitinib."
Journal • Real-world evidence • Atopic Dermatitis • Dermatology • Immunology • Musculoskeletal Pain • Psoriasis • TYK2
|
|
Eita Fujimoto; Hidehisa Saeki; Manami Yoneyama; Mizuki Shiba; Naoko Kanda; Teppei Hagino; Yohei Takahashi
|